Research & development decreased 29.7%
Research & development changed -29.7% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed -29.7% from the comparable as-filed period.
Free-cash-flow proxy changed -11.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Operating cash flow changed -11.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Debt / revenue changed +4052 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current ratio changed +66.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
R&D / revenue changed -333 basis points from the comparable as-filed period.
Free-cash-flow margin changed +993 basis points from the comparable as-filed period.
Operating cash-flow margin changed +958 basis points from the comparable as-filed period.
Selling, general & administrative changed +18.6% from the comparable as-filed period.
Cost of revenue changed +18.4% from the comparable as-filed period.
Operating income changed -5.6% from the comparable as-filed period.
Debt / assets changed +828 basis points from the comparable as-filed period.
Cash / debt changed -3422 basis points from the comparable as-filed period.
Receivables / revenue changed +1205 basis points from the comparable as-filed period.
Working capital / assets changed +1885 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Cash & equivalents changed -16.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Net income changed -6.2% from the comparable as-filed period.
Current long-term debt changed +19.2% from the comparable as-filed period.
Capex / revenue changed -36 basis points from the comparable as-filed period.
Current liabilities changed +5.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Capital expenditure changed +0.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.